ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Challenges With PARP Inhibitors in Ovarian Cancer

Kathleen N. Moore, MD
Published Online:1:58 PM, Wed August 16, 2017

Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.